Patent US5687166A successfully refreshed from Google Patents.
Patent EP0210728A2 successfully refreshed from Google Patents.
EP0210728A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Kit containing polyphosphonate for treating osteoporosis
Assignee: Procter and Gamble Co
•
Filing: 1986-06-04
•
Granted: —
•
Expires: 2006-06-04
Abstract
Abstract Amethodfortreating or preventing osteoporosis utilizing a cyclic regimen comprising alternating for two or more cyclesthe administration of a bone resorption inhibiting polyphosphonate and a no treatment (rest) period. Further disclosed is a kit for use in implementing this method of treatment.
Inventors
- 👤 Lawrence Flora
- 👤 Benjamin Franklin Floyd
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-30 19:20
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/675; A61P; A61P19/00; A61P19/08; A61P19/10; A61P3/00; A61P3/02; A61P43/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
136 words
A kit for use in the treatment or prevention of osteoporosis in humans or lower animals afflicted with or at risk to osteoporosis, according to a regimen comprising two or more cycles, whereby each cycle comprises: (a) a period of from 1 day to 90 days during which a bone resorption inhibiting polyphosphonate is administered daily in a limited and effective amount; followed by (b) a rest period of from 50 days to 120 days, said kit containing the following components: (a) from 1 to 90 daily doses, with each daily dose containing a limited and effective amount of a bone resorption inhibiting polyphosphonate; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 2
Dependent Claim
136 words
A kit for use in the treatment or prevention of osteoporosis in humans or lower animals afflicted with or at risk to osteoporosis, according to a regimen comprising two or more cycles, whereby each cycle comprises: (a) a period of from 1 day to 90 days during which a bone resorption inhibiting polyphosphonate is administered daily in a limited and effective amount; followed by (b) a rest period of from 50 days to 120 days, said kit containing the following components: (a) from 1 to 90 daily doses, with each daily dose containing a limited and effective amount of a bone resorption inhibiting polyphosphonate; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 3
Dependent Claim
68 words
A kit according to Claim 1 containing the following components: (a) from 1 to 90 daily doses of from 0.25 X LED to 10 X LED each of a Cl 2 MDP-like bone resorption inhibiting polyphosphonate; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 4
Dependent Claim
66 words
A kit according to Claim 1 containing the following components: (a) from 1 to 90 daily doses of from 0.25 X LED to 4 X LED each of an EHDP-like bone resorption inhibiting polyphosphonate; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 5
Dependent Claim
66 words
A kit according to Claim 3 containing the following components: (a) from 1 to 30 daily doses of from 0.25 X LED to 2.5 X LED each of an EHDP-like bone resorption inhibiting polyphosphonate; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 6
Dependent Claim
69 words
A kit according to Claim 3 or 4 containing the following components: (a) from 1 to 30 daily doses of from 0.25 X LED to 2.5 X LED each of EHDP, or its pharmaceutically-acceptable salts or esters; (b) from 70 to 100 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 7
Dependent Claim
69 words
A kit according to Claim 2 containing the following components: (a) from 1 to 90 daily doses of from 0.25 X LED to 10 X LED each of Cl 2 MDP, or its pharmaceutically-acceptable salts or esters; (b) from 50 to 120 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 8
Dependent Claim
61 words
A kit according to Claim 6 containing the following components: (a) about 84 daily doses of about 4 mg P/kg each of C1 2 MDP, or its pharmaceutically-acceptable salts or esters; (b) about 84 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 9
Dependent Claim
63 words
A kit according to any of Claims 3 to 5 containing the following components: (a) about 14 daily doses of about 1.25 mg P/kg each of EHDP, or it pharmaceutically-acceptable salts or esters; (b) about 84 daily doses of a placebo or a nutrient supplement; and a means for having the components arranged in a way as to facilitate compliance with the regimen.
Claim 10
Dependent Claim
110 words
A kit according to any of Claims 3 to 6 containing the following components: (a) a card having arranged thereupon 14 daily doses of about 100 mg P each of EHDP, or a pharmaceutically-acceptable salt or ester thereof; (b) 6 cards containing 14 daily doses per card, each dose containing about 1000 mg calcium; (c) said cards stacked such that the card containing the EHDP is on top of the 6 cards containing the daily doses of calcium; and (d) at least two of these stacks arranged in a canister such that removal of the daily doses and cards from the top of the canister facilitates compliance with the regimen.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.